Kymab Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kymab Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10589
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kymab Ltd (Kymab) is a therapeutic antibody company that provides drug and vaccine development solutions. The company offers pipepline of assets in the therapeutic areas of immuno-oncology, inflammatory disease, haematology, and infectious diseases. Its pipeline products includes KY1003-Anti PD-L1, KY1006-Anti-LIGHT, KY1005-Anti-OX40L, KV7005, KY1041, KY1040, KY1036, KY1034, and KY1020, among others. Kymab utilizes kymouse antibody, a transgenic mouse technology platform to generate human antibodies against disease targets. The company’s pipeline treats various diseases including immunology, chronic anemia, chronic pain, dyslipidemia, infectious diseases, immune-oncology, ebola, and orphan oncology, among others. It also offers pre-clinical and clinical development services. The company collaborates with pharmaceutical, biotechnology and academic partners to discover, develop and commercialize monoclonal antibodies in various therapeutic areas. Kymab is headquartered in Cambridge, the UK.

Kymab Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kymab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kymab Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Kymab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kymab Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Kymab Raises USD100.5 Million in Series C Financing 11
Kymab Raises Additional USD50 Million in Series B Financing 13
Kymab Raises USD40 Million in Series B Financing 14
Partnerships 15
Heptares Therapeutics to Form Partnership with Kymab 15
Kymab Enters into Agreement with University of Texas MD Anderson 16
Kymab Enters into Partnership Agreement with Dr Stephen Gillies 17
Licensing Agreements 18
EpimAb Biotherapeutics Enters into Licensing Agreement with Kymab 18
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 19
Kymab Ltd – Key Competitors 20
Kymab Ltd – Key Employees 21
Kymab Ltd – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
May 09, 2017: Kymab Group appoints chief medical officer 23
May 09, 2017: Sonia Quaratino appointed Kymab CMO 24
Jan 23, 2017: Kymab appoints Dr Arndt Schottelius as Executive Vice President Research & Development 25
Government and Public Interest 26
Jan 09, 2017: Kymab expands Infectious Disease Programmes 26
Product News 27
11/08/2017: Kymab to Present Data on its Lead Immuno-oncology Antibody, Demonstrating Strong Potential for Inhibiting Tumour Growth 27
Clinical Trials 28
Jul 31, 2017: Kymab’s KY1005 Antibody in Clinical Trial 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Kymab Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kymab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kymab Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Kymab Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Kymab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kymab Raises USD100.5 Million in Series C Financing 11
Kymab Raises Additional USD50 Million in Series B Financing 13
Kymab Raises USD40 Million in Series B Financing 14
Heptares Therapeutics to Form Partnership with Kymab 15
Kymab Enters into Agreement with University of Texas MD Anderson 16
Kymab Enters into Partnership Agreement with Dr Stephen Gillies 17
EpimAb Biotherapeutics Enters into Licensing Agreement with Kymab 18
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 19
Kymab Ltd, Key Competitors 20
Kymab Ltd, Key Employees 21

List of Figures
Kymab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kymab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kymab Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Kymab Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HomeServe plc (HSV):企業の財務・戦略的SWOT分析
    HomeServe plc (HSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hays plc:企業の戦略・SWOT・財務分析
    Hays plc - Strategy, SWOT and Corporate Finance Report Summary Hays plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Juniper Networks Inc (JNPR):企業の財務・戦略的SWOT分析
    Juniper Networks Inc (JNPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • BP Australia Group Pty Ltd:企業の戦略的SWOT分析
    BP Australia Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Cingulate Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cingulate Therapeutics LLC (Cingulate) is a clinical stage biopharmaceutical company that develops new drug products for the treatment of attention deficit and hyperactivity disorder. The company’s pipeline products comprise CTX-1301 and CTX-1302 utilize precision timed release (PTR) drug de …
  • Statkraft AS:電力:M&Aディール及び事業提携情報
    Summary Statkraft AS (Statkraft), a subsidiary of Statkraft SF, is a power utility which produces electricity and supplies district heating. It generates power from hydro, wind, gas, solar and bio-power sources. The company develops hydroelectric power plants in emerging markets outside Europe. Stat …
  • Churchill Downs Incorporated:企業の戦略・SWOT・財務情報
    Churchill Downs Incorporated - Strategy, SWOT and Corporate Finance Report Summary Churchill Downs Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Eden Innovations (EDE):石油・ガス:M&Aディール及び事業提携情報
    Summary Eden Innovations, formerly Eden Energy Ltd, is a clean energy company that offers carbon nanotube and carbon fibre production, nanomaterial concrete admixtures, hydrogen production, and storage and transport fuel system. The company manufactures and distributes fuel systems, pumps, fuel tank …
  • HitGen LTD-製薬・医療分野:企業M&A・提携分析
    Summary HitGen LTD (HitGen) is a drug company that concentrates on hit identification and lead generation in the early phases of drug discoveries and development. The company offers OpenDEL, a collection of DNA encoded library compounds based on distinct, diverse and drug structures. It provides bio …
  • United Therapeutics Corp (UTHR):医療機器:M&Aディール及び事業提携情報
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …
  • Monsanto Company:企業の戦略・SWOT・財務情報
    Monsanto Company - Strategy, SWOT and Corporate Finance Report Summary Monsanto Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Berkley Renewables Inc (BKS):企業の財務・戦略的SWOT分析
    Berkley Renewables Inc (BKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Exelon Corporation (EXC):電力:M&Aディール及び事業提携情報
    Summary Exelon Corporation (Exelon) is a utility services holding company operating across the energy value chain comprising power generation, distribution, transmission and energy sales. It generates electricity from diverse sources, including nuclear, fossil fuels and renewable energy. Exelon deli …
  • The Mauritius Commercial Bank Limited
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Xcel Energy Inc (XEL):企業の財務・戦略的SWOT分析
    Xcel Energy Inc (XEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • OBJ Ltd (OBJ):医療機器:M&Aディール及び事業提携情報
    Summary OBJ Ltd (OBJ) is a developer of magnetic micro-array drug and ingredient delivery technologies. The company offers services such as drug or ingredient profiling in skin, laboratory facilities and capabilities, formulation development, product development, product optimisation, and pre-commer …
  • Johnson Outdoors Inc (JOUT):企業の財務・戦略的SWOT分析
    Johnson Outdoors Inc (JOUT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • DMC Global Inc (BOOM):企業の財務・戦略的SWOT分析
    Summary DMC Global Inc (DMC), formerly Dynamic Materials Corp is an industrial equipment and machinery company. It manufactures, distributes, and markets explosion welded clad metal plates. The company’s products include oilfield products, explosive metalworking equipment, and AMK welding equipment, …
  • Emerson Electric Co (EMR)-石油・ガス分野:企業M&A・提携分析
    Summary Emerson Electric Co. (Emerson) is a provider of infrastructure technologies and life cycle services for information and communication technology systems. The company offers hardware and software solutions for power, thermal and infrastructure management under the brands of Kop-Flex, jaure, a …
  • Ottogi Corporation:企業の戦略・SWOT・財務情報
    Ottogi Corporation - Strategy, SWOT and Corporate Finance Report Summary Ottogi Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆